Peter Hoffmann

Review of the predictive value of the Langendorff heart model (Screenit system) in assessing the proarrhythmic potential of drugs.

Jean-Pierre Valentin, J. Valentin, T. Hammond, 2004, Journal of pharmacological and toxicological methods.

Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics.

Liudmila Polonchuk, Jean-Pierre Valentin, Hugo M Vargas, 2008, Journal of pharmacological and toxicological methods.

Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends.

P. Hoffmann, Peter Hoffmann, Barbara Warner, 2006, Journal of pharmacological and toxicological methods.

Blinded Test in Isolated Female Rabbit Heart Reliably Identifies Action Potential Duration Prolongation and Proarrhythmic Drugs: Importance of Triangulation, Reverse Use Dependence, and Instability

P. Hoffmann, L. Hondeghem, Peter Hoffmann, 2003, Journal of cardiovascular pharmacology.

Genotoxicity assessment of the antiepileptic drug AMP397, an Ames-positive aromatic nitro compound.

P. Hoffmann, A. Hartmann, Peter Hoffmann, 2002, Mutation research.

Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells.

Martin Traebert, B. Dumotier, M. Traebert, 2004, European journal of pharmacology.

Differentiating electrophysiological effects and cardiac safety of drugs based on the electrocardiogram: a blinded validation.

Martin Traebert, P. Kowey, Donglin Guo, 2012, Heart rhythm.